Bayer logo
US MEDICAL AFFAIRS

Contact Us

Congress Library

European Society of Cardiology - Heart Failure

 European Society of Cardiology - Heart Failure

Oral Sessions

Mihaly Ruppert_ESCHF2026_Ruppert_Efficacy and Safety of FIN Mihaly Ruppert_ESCHF2026_Ruppert_Efficacy and Safety of FIN

Mihaly Ruppert

Efficacy and Safety of Finerenone in Patients with Cardio-Kidney-Metabolic Syndrome and History of Cancer: The FINE-HEART Pooled Analysis

Click to access
Ryohei Ono-Blood Urea Nitrogen to Creatinine Ratio, Clinical Outcomes, and Affect of Finerenone in HFmrEF/HFpEF: Findings in FINEARTS-HF Ryohei Ono-Blood Urea Nitrogen to Creatinine Ratio, Clinical Outcomes, and Affect of Finerenone in HFmrEF/HFpEF: Findings in FINEARTS-HF

Ryohei Ono

Blood Urea Nitrogen to Creatinine Ratio, Clinical Outcomes, and Affect of Finerenone in HFmrEF/HFpEF: Findings in FINEARTS-HF

Click to access
John Ostrominski-ESCHF2026_Ostrminski_Obesity and Health Status in HF John Ostrominski-ESCHF2026_Ostrminski_Obesity and Health Status in HF

John Ostrominski

Obesity and Health Status in Heart Failure with Preserved Ejection Fraction

Click to access
Ragnhild Helseth-Viral Respiratory Tract Infections in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Trial Ragnhild Helseth-Viral Respiratory Tract Infections in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Trial

Ragnhild Helseth

Viral Respiratory Tract Infections in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Trial

Click to access

Posters

A Michel-IMAGE 5_Michel_Contemporary Characteristics A Michel-IMAGE 5_Michel_Contemporary Characteristics

A Michel

Contemporary Characteristics and Treatment Patterns of Patients with HFmrEF and HFpEF in Germany: A Cross-Sectional Survey

Click to access
John Ostrominski-ESCHF2026_Ostrominski_FIN and All-Cause Hospitalization John Ostrominski-ESCHF2026_Ostrominski_FIN and All-Cause Hospitalization

John Ostrominski

Finerenone and All-Cause Hospitalization in Cardiovascular-Kidney Metabolic Disease.

Click to access
Giulia Ferrannini Type 2 Diabetes and Chronic Kidney Disease Combinations in Heart Failure Across the Ejection Fraction Spectrum: Giulia Ferrannini Type 2 Diabetes and Chronic Kidney Disease Combinations in Heart Failure Across the Ejection Fraction Spectrum:

Giulia Ferrannini

Type 2 Diabetes and Chronic Kidney Disease Combinations in Heart Failure Across the Ejection Fraction Spectrum: Clinical Associations, Medication Use, and Cause-Specific Outcomes: A Contemporary, Real-World Analysis of the Swedish Heart Failure Registry

Click to access
AP Ambrosy - ESCHF2026_Ambrosy_Temporal Trends in Mineralocorticoids AP Ambrosy - ESCHF2026_Ambrosy_Temporal Trends in Mineralocorticoids

AP Ambrosy

Temporal Trends in Mineralocorticoid Receptor Antagonist Use Among Patients with Heart Failure in a Community-Based Cohort

Click to access
John Ostrominski Undiagnosed Chronic Kidney Disease, Outcomes, and Finerenone in Heart Failure with Preserved Ejection Fraction John Ostrominski Undiagnosed Chronic Kidney Disease, Outcomes, and Finerenone in Heart Failure with Preserved Ejection Fraction

John Ostrominski

Undiagnosed Chronic Kidney Disease, Outcomes, and Finerenone in Heart Failure with Preserved Ejection Fraction

Click to access

Follow Us

Twitter (X) Icon
YouTube Icon
LinkedIn Icon

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

US Medical Affairs QR Code

Copyright © 2026 Bayer

Bayer and the Bayer Cross are registered trademarks of Bayer.

sitemap